SPINOZA Trial Start Could Be A Game Changer For NewAmsterdam Pharma Stock (NAMS)

• NewAmsterdam Pharma recently dosed the first participant in SPINOZA, a 400-patient Phase 2b trial testing obicetrapib in preclinical Alzheimer’s disease over 52 weeks with a biomarker-focused design.
• The move repurposes an oral CETP inhibitor originally developed for LDL lowering into Alzheimer’s prevention research, potentially widening obicetrapib’s addressable patient pool if future data support dual cardiometabolic and neurodegeneration use.
• The focus now shifts to how the SPINOZA Alzheimer’s trial could reshape NewAmsterdam Pharma’s broader investment narrative around obicetrapib.

Spot emerging biopharma stories alongside NewAmsterdam Pharma by scanning a curated set of 20 high quality undiscovered gems featuring strong fundamentals and under-the-radar pipelines.

NewAmsterdam Pharma Investment Narrative Recap

To back NewAmsterdam Pharma, you need to believe obicetrapib can support a broad cardiometabolic franchise and potentially extend into Alzheimer’s prevention. The SPINOZA start adds a second pillar to that story, but it does not change the reality that the near term hinges on execution in hyperlipidemia and on maintaining operating discipline as the organization scales.

The main short term catalyst remains the set of European Commission decisions on obicetrapib in 2H 2026 and the first launches with Menarini in late Q4 2026. The biggest risk remains clear. PREVAIL outcomes data and future adoption will need to justify current spend, ongoing losses and future equity dilution.

The SPINOZA launch sits alongside other important work such as the PREVAIL cardiovascular outcomes trial and late stage programs including REMBRANDT and RUBENS. Among these, PREVAIL remains the most relevant reference point when considering catalysts, because pricing, reimbursement and long term revenue expectations for NewAmsterdam Pharma largely tie back to cardiovascular outcomes.

SPINOZA adds a new potential use case, but the company still centers on PREVAIL and upcoming European regulatory decisions. Positive regulatory outcomes and disciplined execution on the Menarini rollout could help start converting the large hyperlipidemia population into royalty and supply income, while any disappointment in PREVAIL would challenge that entire earnings roadmap.

What The Current Analyst Models Assume For NewAmsterdam Pharma

NewAmsterdam Pharma's narrative projects US$528.0 million of revenue and US$81.1 million of earnings by 2029. That profile is tied to analyst assumptions of yearly revenue growth of 320.1%, and an earnings swing of roughly US$341 million from a current loss of US$259.5 million to the projected profit.

Uncover why NewAmsterdam Pharma's fair value indicates a 136% potential upside to its current price, which may not last much longer.

Exploring Other Perspectives

For NewAmsterdam Pharma, the most optimistic analysts latch onto SPINOZA as a potential second act. They already modeled revenue of about US$1.4b and earnings of roughly US$742.9 million by 2029 before this Alzheimer’s trial even started. You can treat that as a reminder that opinion ranges are wide and worth comparing side by side.

Explore 4 other NewAmsterdam Pharma fair value estimates, including one that suggests as much as 4949% upside from the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view.

• A great starting point for your NewAmsterdam Pharma research is our analysis highlighting 3 key rewards that could impact your investment decision.
• See our latest analysis for NewAmsterdam Pharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate NewAmsterdam Pharma's overall financial health at a glance.

Looking for more investment ideas beyond NewAmsterdam Pharma?

Once you have a view on NewAmsterdam Pharma, it can help to widen the lens and compare it with other companies that fit different risk and return profiles using the Simply Wall St Screener.

• For investors hunting for potential higher risk, higher reward opportunities, scan a focused group of 14 elite penny stocks with strong financials that already screen well on financial quality.
• If capital preservation ranks high on your priority list, sort through 31 resilient stocks with low risk scores to see which businesses currently align with a more defensive approach.
• When you want balance sheet resilience and cleaner fundamentals, filter candidates using the list of solid balance sheet and fundamentals (25 results) to round out your watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com